Universal Flu Vaccine Shown ‘Feasible’ And Safe In Phase I Study, NIH’s Fauci Says
This article was originally published in The Pink Sheet Daily
Executive Summary
NIH and BARDA will conduct a clinical study of a universal vaccine candidate manufactured by CSL in the next flu season; CDC official explains why this year’s flu vaccine was not altered when mismatch to circulating virus was detected.